# gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females

> **NCT00133497** · PHASE2 · COMPLETED · sponsor: **National Institute of Allergy and Infectious Diseases (NIAID)** · enrollment: 409 (actual)

## Conditions studied

- Cytomegalovirus Infections

## Interventions

- **BIOLOGICAL:** MF-59
- **DRUG:** Placebo
- **BIOLOGICAL:** CMV gB vaccine

## Key facts

- **NCT ID:** NCT00133497
- **Lead sponsor:** National Institute of Allergy and Infectious Diseases (NIAID)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2006-06
- **Primary completion:** 2013-06
- **Final completion:** 2013-06
- **Target enrollment:** 409 (ACTUAL)
- **Last updated:** 2017-07-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00133497

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00133497, "gB/MF59 Vaccine in Preventing Cytomegalovirus Infection in Healthy Adolescent Females". Retrieved via AI Analytics 2026-06-12 from https://api.ai-analytics.org/clinical/NCT00133497. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*